Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect
Purpose. The aim of the study is to assess netarsudil’s intraocular pressure (IOP)-lowering potential when prescribed as an adjunctive agent, to examine the effect of baseline IOP on patients’ response to netarsudil, and to explore patients’ characteristics predictive of pronounced responses to neta...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2022/6925027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552846888796160 |
|---|---|
| author | Sandy Samuel Hani El Helwe Cameron E. Neeson Nathan Hall Ryan Sameen Meshkin Nino Odishelidze Rebecca Ye Ta C. Chang David Solá-Del Valle |
| author_facet | Sandy Samuel Hani El Helwe Cameron E. Neeson Nathan Hall Ryan Sameen Meshkin Nino Odishelidze Rebecca Ye Ta C. Chang David Solá-Del Valle |
| author_sort | Sandy Samuel |
| collection | DOAJ |
| description | Purpose. The aim of the study is to assess netarsudil’s intraocular pressure (IOP)-lowering potential when prescribed as an adjunctive agent, to examine the effect of baseline IOP on patients’ response to netarsudil, and to explore patients’ characteristics predictive of pronounced responses to netarsudil. Methods. This is a single-center, multiprovider retrospective cohort study set at Massachusetts Eye and Ear. Patients with a diagnosis of glaucoma or ocular hypertension on netarsudil and at least one other hypotensive agent for glaucoma who had at least one month of follow-up were included. Patients with additional procedures or glaucoma medication changes were excluded. The main outcome measures were IOP reduction, Kaplan–Meier survival analyses, netarsudil responder type, and complication rates. Results. 236 eyes of 236 patients were included. The mean baseline IOP was 19.06 ± 4.6 mmHg on an average of 4 ocular hypotensive medications. 196 (83.1%) patients experienced IOP reduction at the first follow-up visit of 2.84 ± 0.30 mmHg at 55.66 ± 51.89 days. IOP reduction at the second visit among these patients was 3.01 ± 0.44 mmHg at 133.24 ± 77.63 days. After starting netarsudil, 59% had a sustained response (median duration of 315 days), 25% had a robust response (>20% IOP reduction for at least 80% of visits), and 10% had a super response (>20% and >10 mmHg IOP reduction). Netarsudil was effective as an adjunctive therapy across all baseline IOP categories with greater relative IOP reduction in higher baseline IOP groups. Conclusions. Netarsudil is an effective adjunctive glaucoma therapy. IOP reductions between 2 and 3 mmHg are typical, but a minority had more pronounced and sustained effects (>10 mmHg). Further analysis is needed to assess specific demographic and clinical factors predictive of these robust responses. |
| format | Article |
| id | doaj-art-525545c8e49c4ad083eb39a8d2c1f2dd |
| institution | Kabale University |
| issn | 2090-0058 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-525545c8e49c4ad083eb39a8d2c1f2dd2025-02-03T05:57:38ZengWileyJournal of Ophthalmology2090-00582022-01-01202210.1155/2022/6925027Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering EffectSandy Samuel0Hani El Helwe1Cameron E. Neeson2Nathan Hall3Ryan Sameen Meshkin4Nino Odishelidze5Rebecca Ye6Ta C. Chang7David Solá-Del Valle8Massachusetts Eye and EarMassachusetts Eye and EarMassachusetts Eye and EarMassachusetts Eye and EarMassachusetts Eye and EarMassachusetts Eye and EarMassachusetts Eye and EarBascom Palmer Eye InstituteMassachusetts Eye and EarPurpose. The aim of the study is to assess netarsudil’s intraocular pressure (IOP)-lowering potential when prescribed as an adjunctive agent, to examine the effect of baseline IOP on patients’ response to netarsudil, and to explore patients’ characteristics predictive of pronounced responses to netarsudil. Methods. This is a single-center, multiprovider retrospective cohort study set at Massachusetts Eye and Ear. Patients with a diagnosis of glaucoma or ocular hypertension on netarsudil and at least one other hypotensive agent for glaucoma who had at least one month of follow-up were included. Patients with additional procedures or glaucoma medication changes were excluded. The main outcome measures were IOP reduction, Kaplan–Meier survival analyses, netarsudil responder type, and complication rates. Results. 236 eyes of 236 patients were included. The mean baseline IOP was 19.06 ± 4.6 mmHg on an average of 4 ocular hypotensive medications. 196 (83.1%) patients experienced IOP reduction at the first follow-up visit of 2.84 ± 0.30 mmHg at 55.66 ± 51.89 days. IOP reduction at the second visit among these patients was 3.01 ± 0.44 mmHg at 133.24 ± 77.63 days. After starting netarsudil, 59% had a sustained response (median duration of 315 days), 25% had a robust response (>20% IOP reduction for at least 80% of visits), and 10% had a super response (>20% and >10 mmHg IOP reduction). Netarsudil was effective as an adjunctive therapy across all baseline IOP categories with greater relative IOP reduction in higher baseline IOP groups. Conclusions. Netarsudil is an effective adjunctive glaucoma therapy. IOP reductions between 2 and 3 mmHg are typical, but a minority had more pronounced and sustained effects (>10 mmHg). Further analysis is needed to assess specific demographic and clinical factors predictive of these robust responses.http://dx.doi.org/10.1155/2022/6925027 |
| spellingShingle | Sandy Samuel Hani El Helwe Cameron E. Neeson Nathan Hall Ryan Sameen Meshkin Nino Odishelidze Rebecca Ye Ta C. Chang David Solá-Del Valle Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect Journal of Ophthalmology |
| title | Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect |
| title_full | Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect |
| title_fullStr | Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect |
| title_full_unstemmed | Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect |
| title_short | Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect |
| title_sort | netarsudil as an adjunctive therapy efficacy and factors contributing to a favorable iop lowering effect |
| url | http://dx.doi.org/10.1155/2022/6925027 |
| work_keys_str_mv | AT sandysamuel netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT hanielhelwe netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT cameroneneeson netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT nathanhall netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT ryansameenmeshkin netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT ninoodishelidze netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT rebeccaye netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT tacchang netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect AT davidsoladelvalle netarsudilasanadjunctivetherapyefficacyandfactorscontributingtoafavorableioploweringeffect |